[Skip to Navigation]
March 1988


Arch Dermatol. 1988;124(3):321-322. doi:10.1001/archderm.1988.01670030009003

To the Editor.—  I read the editorial on lindane by Dr Rasmussen in the August 1987 issue of the Archives1 with interest. His advice may not be as prudent as the situation dictates.In the same issue, there was an article by Freedmen,2 which, besides detailing his case report, gave a careful, cautioned review of the literature and advice for the continued use of a drug. For this reason, it was difficult to understand the defensive stance taken in Rasmussen's editorial, which is filled with words like "very large amounts," "very small quantities," "frequent closely spaced applications," "toxic reactions occur rarely and are so uncommon that they usually merit a case report," etc.These terms, typical of the entire editorial, are highly subjective and judgmental when they are not accompanied by quantitative parameters. From his references, one may conclude that Rasmussen is unaware of the total number of

Add or change institution